8-K: Theravance Biopharma Settles Patent Litigation with Orbicular Over YUPELRI Inhalation Solution

Theravance Biopharma and Mylan have reached a settlement with Orbicular Pharmaceutical Technologies, granting them a license to market a generic version of YUPELRI starting April 23, 2039.

Summary

• Theravance Biopharma, along with its subsidiaries, and Mylan have entered into a settlement agreement with Orbicular Pharmaceutical Technologies regarding patent litigation related to YUPELRI (revefenacin) inhalation solution.
• The settlement resolves a lawsuit initiated by Theravance and Mylan against Orbicular for filing an abbreviated new drug application (ANDA) to market a generic version of YUPELRI before the expiration of the relevant patents.
• Under the agreement, Theravance and Mylan have granted Orbicular a royalty-free, non-exclusive license to manufacture and market its generic version of YUPELRI in the United States starting April 23, 2039.
• This license is non-sublicensable and non-transferable, with standard exceptions.
• The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
• Patent litigation remains ongoing against four other ANDA filers: Cipla Limited, Eugia Pharma Specialities Ltd., Lupin Inc., and Mankind Pharma Ltd.

Sentiment

Score: 6

Explanation: The settlement is a mixed bag. It resolves one legal issue but introduces future competition. The long lead time before generic entry mitigates some of the negative impact.

Positives

• The settlement with Orbicular provides clarity on the patent landscape for YUPELRI.
• The agreement allows for a future generic version of YUPELRI, potentially increasing market access after 2039.
• Resolving the litigation with Orbicular removes one legal uncertainty for Theravance and Mylan.

Negatives

• The settlement allows a generic version of YUPELRI to enter the market in 2039, which will likely reduce future revenue for Theravance and Mylan.
• Patent litigation remains ongoing against four other ANDA filers, indicating continued legal expenses and uncertainty.

Risks

• The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, which could potentially impact the agreement.
• Ongoing patent litigation against other ANDA filers could result in further settlements or unfavorable outcomes.
• The entry of generic competition in 2039 will likely impact the profitability of YUPELRI.

Future Outlook

The settlement allows for a generic version of YUPELRI to enter the market in 2039, which will likely impact future revenue for Theravance and Mylan. The company still faces ongoing patent litigation with other ANDA filers.

Industry Context

This settlement is part of the typical process in the pharmaceutical industry where generic drug manufacturers challenge patents of branded drugs. The Hatch-Waxman Act facilitates this process, aiming to balance innovation with access to affordable medicines. This settlement is a common outcome of such litigation.

Comparison to Industry Standards

• The settlement agreement is consistent with industry norms for resolving patent disputes related to generic drug applications.
• The licensing of a generic version of YUPELRI with a future launch date is a common approach to managing patent expirations and market competition.
• The ongoing litigation with other ANDA filers is also typical in the pharmaceutical industry, where multiple generic companies often seek to enter the market.

Legal Proceedings

• Theravance and Mylan have settled patent litigation with Orbicular.
• Patent litigation remains ongoing against Cipla Limited, Eugia Pharma Specialities Ltd., Lupin Inc., and Mankind Pharma Ltd.

Stakeholder Impact

• Shareholders may see a long-term impact on revenue due to the future generic competition.
• Customers may benefit from a generic version of YUPELRI becoming available in the future.
• Employees may not see any immediate impact, but long-term revenue changes could affect the company.

Next Steps

• The settlement agreement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission.
• Theravance and Mylan will continue to litigate against the remaining four ANDA filers.

Key Dates

Keywords

YUPELRI, revefenacin, patent litigation, settlement agreement, generic, ANDA, Theravance Biopharma, Mylan, Orbicular, Hatch-Waxman Act